Mirum Pharmaceuticals, Inc. MIRM Volixibat — Payments for achievement of various milestones
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Mirum Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept mirm:PaymentsForAchievementOfVariousClinicalDevelopmentRegulatoryAndCommercialMilestones.
The official record: Mirum Pharmaceuticals, Inc.’s 10-K, filed February 25, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mirum Pharmaceuticals, Inc.'s volixibat — payments for achievement of various milestones.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mirum Pharmaceuticals, Inc.'s volixibat — payments for achievement of various milestones?
- Mirum Pharmaceuticals, Inc. (MIRM) reported volixibat — payments for achievement of various milestones of $25.38M in Q4 2025.
- How has Mirum Pharmaceuticals, Inc.'s volixibat — payments for achievement of various milestones changed year-over-year?
- Mirum Pharmaceuticals, Inc.'s volixibat — payments for achievement of various milestones increased by 17.3% year-over-year, from $21.63M to $25.38M.
- What does volixibat — payments for achievement of various milestones mean?
- Reflects the actual cash outflows disbursed to third parties upon the successful attainment of predetermined milestones for the Volixibat program. These payments are typically stipulated in collaboration or in-licensing agreements to reward progress in clinical trials or regulatory filings. Tracking these payments provides insight into the realized capital expenditure required to advance the asset toward market approval.